In:
The Laryngoscope, Wiley, Vol. 127, No. 5 ( 2017-05), p. 1061-1067
Abstract:
The purpose of this study was to report the outcomes of a retrospective consecutive cohort study of patients with T1N0M0 glottic carcinoma treated with 4‐MV or 6‐MV radiotherapy. Study Design Retrospective case–control study. Methods This was a retrospective review of all patients with T1N0M0 glottic carcinoma treated with radiotherapy between January 2000 and December 2012 in the Department of Radiation Oncology at National Cancer Center Singapore. A total of 124 patients were included. Clinical endpoints of interest were: local control (LC), overall survival (OS), and disease‐specific survival (DSS). Other prognostic factors for LC were also analyzed: age, gender, smoking status, T substage, dose fraction, field size, anterior commissure involvement, total dose, and overall treatment time. Results Six‐megavolt photon radiotherapy was used in 73 patients and 4‐MV photon radiotherapy in 51 patients. Median follow‐up was 4.9 years. The 5‐year LC and OS were as follows: 4 MV, 91.6% and 83.4%; 6 MV, 88.8% and 82.8%; and the 5‐year LC, OS, and DSS for all patients were 90.4%, 83.3%, and 98.3%. There was no significant difference in LR and OS between 4‐MV and 6‐MV radiotherapy ( P = .92, P = .16, respectively). In the univariate analysis of LC, none of the prognostic factors was statistically significant. Twenty patients (23%) developed second primary cancers, the majority in the lungs. Conclusions Six‐megavolt photon radiotherapy yields comparable results to 4‐MV photons. Bolus and computed tomographic simulation are useful to ensure adequate dose coverage of target volume. Follow‐up postradiotherapy should incorporate chest imaging, smoking cessation advice, and thyroid function test. Level of Evidence 4 Laryngoscope , 127:1061–1067, 2017
Type of Medium:
Online Resource
ISSN:
0023-852X
,
1531-4995
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
2026089-1
Permalink